<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572870</url>
  </required_header>
  <id_info>
    <org_study_id>450-10 CTIL</org_study_id>
    <secondary_id>Chit 1</secondary_id>
    <nct_id>NCT01572870</nct_id>
  </id_info>
  <brief_title>Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients</brief_title>
  <official_title>Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <brief_summary>
    <textblock>
      Title: Duplication in Chitotriosidase (CHIT1) Gene and the Risk for Aspergillus Lung Disease&#xD;
      in CF Patients.&#xD;
&#xD;
      Aim: To evaluate the link between CHIT1 duplication in CF patients and the predisposition to&#xD;
      ABPA or persistent Aspergillus infection.&#xD;
&#xD;
      Patients: 40 CF patients. Design: Observational, single visit. Methods: All patients will be&#xD;
      assessed for pulmonary function tests (PFT), sputum cultures, and blood tests for: CHIT1&#xD;
      duplication, immunoglobulin E (IgE) and Eosinophils levels. Part of the patients will be&#xD;
      assessed for RAST, skin prick test.&#xD;
&#xD;
      Primary outcome measure is the difference in CHIT1 genotyping between the groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Duplication in Chitotriosidase (CHIT1) Gene and the Risk for Aspergillus Lung Disease&#xD;
      in CF Patients.&#xD;
&#xD;
      Introduction: Chitinases are the enzymes that digest the chitin polymer. Plants use CHIT1 as&#xD;
      an important innate defense mechanism against fungi. CHIT1 is the major chitinase in the&#xD;
      human airways.Variation in the coding region, with 24-bp duplication allele results in a&#xD;
      reduced CHIT1 activity. Recently, CHIT1 duplication was found in 6/6 patients with severe&#xD;
      asthma and fungal sensitization Aspergillus often persists in the respiratory tract of&#xD;
      patients with Cystic Fibrosis (CF) and may cause allergic broncho pulmonary aspergillosis&#xD;
      (ABPA).&#xD;
&#xD;
      Aim: to evaluate the link between CHIT1 duplication in CF patients and the predisposition to&#xD;
      ABPA or persistent Aspergillus infection.&#xD;
&#xD;
      Patients: 40 CF patients divided to three groups .Group 1: patients who have neither ABPA nor&#xD;
      Aspergillus infection in the past (the control group).Group 2: patients with persistent&#xD;
      Aspergillus infection, without ABPA. Group 3: patients with current or past ABPA.&#xD;
&#xD;
      Design: Observational, single visit. Methods: All patients will be assessed for pulmonary&#xD;
      function tests (PFT), sputum cultures, and blood tests for: CHIT1 duplication, IgE and&#xD;
      Eosinophils levels.&#xD;
&#xD;
      Patient's characteristics including demographics, CF mutations, pancreatic status and sweat&#xD;
      test will be derived from the charts.&#xD;
&#xD;
      Patients with ABPA as well as Aspergillus infection had also radioallergosorbent test (RAST)&#xD;
      for molds, as well as skin prick test for Aspergillus and blood Galactomannan.&#xD;
&#xD;
      The primary outcome measure is the difference in CHIT1 genotyping between the groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CHIT1 genotyping</measure>
    <time_frame>Baseline</time_frame>
    <description>In peripheral blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgE</measure>
    <time_frame>Baseline</time_frame>
    <description>peripheral blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils</measure>
    <time_frame>Baseline</time_frame>
    <description>peripheral blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin test for aspergillus</measure>
    <time_frame>Baseline</time_frame>
    <description>skin prick test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>galactomannan</measure>
    <time_frame>Baseline</time_frame>
    <description>peripheral blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary function test</measure>
    <time_frame>Baseline</time_frame>
    <description>spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAST test</measure>
    <time_frame>Baseline</time_frame>
    <description>Radioallergosorbent test (RAST) for molds</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Chit1</condition>
  <arm_group>
    <arm_group_label>No ABPA nor Aspergillus infection</arm_group_label>
    <description>CF patients who had neither ABPA nor Aspergillus infection in the past (the control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>persistent Aspergillus infection, without ABPA</arm_group_label>
    <description>CF patients with persistent Aspergillus infection, without ABPA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current or past ABPA infection</arm_group_label>
    <description>CF patients with current or past ABPA</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        40 Cystic Fibrosis patients: Group 1: 22 CF patients who had neither ABPA nor Aspergillus&#xD;
        infection in the past.&#xD;
&#xD;
        Group 2: 12 CF patients with persistent Aspergillus infection, without ABPA. Group 3: 6 CF&#xD;
        patients with current or past ABPA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of Cystic Fibrosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to produce sputum, or previous history of lung transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lea Bentur, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chit1</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Allergic Bronchopulmonary Aspergillosis (ABPA)</keyword>
  <keyword>Aspergillus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

